CompletedInterventionalPhase 2Last updated Oct 8, 2012

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)

Overview

ClinicalTrials.gov ID: NCT00003549
Lead Sponsor: SWOG Cancer Research NetworkNETWORK
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.
Study Type

Status

Overall Status: Completed
Start Date: Oct 1998
Primary Completion Date: Sep 2001Actual
Completion Date: Jan 2003Actual

Study Record Dates

First Submitted: Nov 1, 1999
First Submitted that Met QC Criteria: Jun 23, 2004
First Posted: Jun 24, 2004Estimated
Last Update Submitted that Met QC Criteria: Oct 5, 2012
Last Update Posted: Oct 8, 2012Estimated
Last Verified: Oct 2012

NCT00002498Unknown status

Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer

NCT00036868Completed

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT02584829Terminated

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

NCT00004141Completed

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00002557Unknown status

Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides

NCT01227408Withdrawn

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer